CAS
BIIB icon

CTC Alternative Strategies’s Biogen BIIB Stock Holding History

CTC Alternative Strategies’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,500
Closed -$323K – 104
2013
Q2 		$323K Buy
+1,500
New +$321K 0.09% 111

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CTC Alternative Strategies's BIIB Position: Q3 2013 in Review

CTC Alternative Strategies sold out of Biogen (BIIB) in Q3 2013, closing a stake of 1,500 shares — an estimated $323K sold.

CTC Alternative Strategies first reported a position in BIIB in Q2 2013 and held it in 1 quarter. The position peaked at $323K in Q2 2013. 656 funds tracked by Wall St. Rank hold BIIB as of Q3 2013.

  • CTC Alternative Strategies reported no remaining Biogen position as of Q3 2013 after selling out during the quarter.
  • CTC Alternative Strategies sold 1,500 Biogen shares in Q3 2013, an estimated $323K.
  • CTC Alternative Strategies first reported a position in Biogen in Q2 2013 and held it in 1 quarter.
  • CTC Alternative Strategies's Biogen position peaked at $323K in Q2 2013.
  • 656 funds tracked by Wall St. Rank held Biogen as of Q3 2013.

Based on CTC Alternative Strategies's 13F filing for Q3 2013, filed 31 Oct 2013.